In vitro evaluation of efficacy of 5 methods of disinfection on mouthpieces and facemasks contaminated by strains of cystic fibrosis patients.
ABSTRACT Home-nebulizers are a potential source of bacterial infection of the respiratory tract in patients suffering from cystic fibrosis. Recommendations for disinfecting this equipment are often arbitrary and sometimes contradictory.
To assess in vitro the effectiveness of 5 methods of disinfecting this equipment.
160 mouthpieces and 160 masks of nebulizers were artificially and massively contaminated with 16 strains of germs found in patients with cystic fibrosis (Staphylococcus aureus, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Burkholderia cenocepacia, Alcaligenes xylosoxydans). A controlled comparison was carried out of the five methods of disinfection (hypochlorite solution (0.02% active chlorine), acetic acid 3.5%, Hexanios 0.5%, washing-up detergent 0.5% and a dishwasher), tested with and without drying. Standardised bacteriological sampling took place 4 h after disinfecting.
Following treatment, the disappearance of the germ was recorded in 84.1% of cases, and effective disinfecting (reduction>5 log CFU/mL) in another 10.6%. Disinfection failure (5.3%) was found almost only in the case of acetic acid against Staphylococcus aureus.
With the exception of acetic acid, the methods of disinfecting tested in this study appeared to be effective against common bacterial pathogens in cystic fibrosis.
Article: Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus.[show abstract] [hide abstract]
ABSTRACT: In cystic fibrosis inhalation of drugs for the treatment of CF related lung disease has been proven to be highly effective. Consequently, an increasing number of drugs and devices have been developed for CF lung disease or are currently under development. In this European consensus document we review the current status of inhaled medication in CF, including the mechanisms of action of the various drugs, their modes of administration and indications, their effects on lung function, exacerbation rates, survival and quality of life, as well as side effects. Specifically we address antibiotics, mucolytics/mucous mobilizers, anti-inflammatory drugs, bronchodilators and combinations of solutions. Additionally, we review the current knowledge on devices for inhalation therapy with regard to optimal particle sizes and characteristics of wet nebulisers, dry powder and metered dose inhalers. Finally, we address the subject of testing new devices before market introduction.Journal of cystic fibrosis: official journal of the European Cystic Fibrosis Society 07/2009; 8(5):295-315. · 3.19 Impact Factor